Lupus erythematosus profundus (lupus panniculitis) induced by interferon-β in a multiple sclerosis patient

Journal of Clinical Neuroscience

Volumn 14, Issue 10, 2007, Pages 997-1000

  Gono, Takahisa ^a   Matsuda, Masayuki ^a   Shimojima, Yasuhiro ^a   Kaneko, Kazuma ^a   Murata, Hiroshi ^a   Ikeda, Shu ichi ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Interferon ; Lupus erythematosus profundus; Multiple sclerosis

Indexed keywords

C REACTIVE PROTEIN; INTERFERON BETA SERINE; METHYLPREDNISOLONE; PREDNISOLONE;

ADULT; ANAMNESIS; ARTICLE; BABINSKI REFLEX; BODY REGIONS; CASE REPORT; CLINICAL FEATURE; DISCOID LUPUS ERYTHEMATOSUS; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPESTHESIA; HYPOALGESIA; LABORATORY TEST; LUPUS ERYTHEMATOSUS PROFUNDUS; MULTIPLE SCLEROSIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RECURRENT DISEASE; RETROBULBAR OPTIC NEUROPATHY; SKIN NODULE; SPINAL CORD DISEASE; TENDON REFLEX; TREATMENT DURATION;

ADULT; CHEMOTAXIS, LEUKOCYTE; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MULTIPLE SCLEROSIS; PANNICULITIS, LUPUS ERYTHEMATOSUS; SUBCUTANEOUS FAT; WITHHOLDING TREATMENT;

EID: 34548273963     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocn.2006.07.011     Document Type: Article

References (14)

1. Vial T., and Descotes J. Immune-mediated side-effects of cytokines in humans. Toxicology 105 (1995) 31-57
2. Walther E.U., and Hohlfeld R. Multiple sclerosis. Side effects of interferon beta therapy and their management. Neurology 53 (1999) 1622-1627
3. Blanco P., Palucka A.K., Gill M., et al. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 294 (2001) 1540-1543
4. Nousari H.C., Kimyai-Asadi A., and Tausk F.A. Subacute cutaneous lupus erythematosus associated with interferon beta-1a. Lancet 352 (1998) 1825-1826
5. Schmutz J., Barbaud A., and Trechot P. Subacute cutaneous lupus erythematosus and interferon beta-1a. Ann Dermatol Venereol 127 (2000) 237
6. Crispin J.C., and Diaz-Jouanen E. Systemic lupus erythematosus induced by therapy with interferon-beta in a patient with multiple sclerosis. Lupus 14 (2005) 495-496
7. Polman C.H., Kappos L., Dahlke F., et al. Interferon beta-1b treatment does not induce autoantibodies. Neurology 64 (2005) 996-1000
8. Kivisakk P., Lundahl J., von Heigl Z., et al. No evidence for increased frequency of autoantibodies during interferon-beta 1b treatment of multiple sclerosis. Acta Neurol Scand 97 (1998) 320-323
9. Colosimo C., Pozzilli C., Frontoni M., et al. No increase of serum autoantibodies during therapy with recombinant human interferon-beta 1a in relapsing-remitting multiple sclerosis. Acta Neurol Scand 96 (1997) 372-374
10. Hirohata S., and Kosaka M. Association of anti-Sm antibodies with organic brain syndrome secondary to systemic lupus erythematosus. Lancet 343 (1994) 796
11. Swaak A.J., Huysen V., Nossent J.C., et al. Antinuclear antibody profiles in relation to specific disease manifestations of systemic lupus erythematosus. Clin Rheumatol 9 (1990) 82-94
12. Silva L.M., Garcia A.B., and Donadi E.A. Increased lymphocyte death by neglect-apoptosis is associated with lymphopenia and autoantibodies in lupus patients presenting with neuropsychiatric manifestations. J Neurol 249 (2002) 1048-1054
13. McLean B.N., Miller D., and Thompson E.J. Oligoclonal banding of IgG in CSF, blood-brain barrier function, and MRI findings in patients with sarcoidosis, systemic lupus erythematosus, and Behcet's disease involving the nervous system. J Neurol Neurosurg Psychiatry 58 (1995) 548-554
14. Kurtzke J.F. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology (Cleveland) 33 (1983) 1444-1452